logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回期刊详情
B

Biologics-Targets & Therapy

IF3.4
论文数9
被引数
期刊论文 9
发表时间
delete
Beyond Eczema Control: Long-Term Outcomes of Dupilumab Therapy in Six Patients with Netherton Syndrome超越湿疹控制：Dupilumab疗法在6例Netherton综合征患者中的长期疗效
deleteBiologics-Targets & Therapy
IF3.4
delete2026-10-12
delete0
deleteOAAI
deleteKamila Zawadzińska-Halat; Magdalena Stec; Katarzyna Poznańska-Kurowska; Maciej Pastuszczak
delete分享
delete收藏
Real-World Outcomes of a Non-Medical Switch to Adalimumab-Atto Biosimilar: Safety, Effectiveness, and Treatment Persistence in an Adult Saudi Tertiary Care Population非医疗原因转换为阿达木单抗-Atto生物类似物的真实世界结局：安全性、有效性和治疗持续性在成年沙特三级护理人群中的应用
deleteBiologics-Targets & Therapy
IF3.4
delete2026-10-12
delete0
deleteOAAI
deleteAlhanouf Almousa; Mohamed Ahmed; Rayd Abdulaziz Almehizia; Meshal Aldurayhim; Gamal Mohamed; Almutairdi Abdulelah; Yousef Binamer; Ahmed Alshaikh
delete分享
delete收藏
Apatinib Plus PD-1 Blockade versus Chemotherapy After Prior Immunotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Cohort Study阿帕替尼联合PD-1阻断剂与化疗在先前接受免疫治疗后的晚期胃或胃食管结合部腺癌中的比较：一项回顾性队列研究
deleteBiologics-Targets & Therapy
IF3.4
delete2026-09-25
delete0
deleteOAAI
deleteRui-Xin Li, Hong-Wei Yang, Yun-Fei Zhang, Xin-Yu Liu
delete分享
delete收藏
Oral Acitretin Combined with Topical 0.1% Tretinoin Cream for Facial Basal Cell Carcinoma in an Elderly Patient: A Case Report口服阿维A酸联合0.1%维A酸乳膏治疗老年患者面部基底细胞癌：病例报告
deleteBiologics-Targets & Therapy
IF3.4
delete2026-08-14
delete0
deleteOAAI
deleteZhirong Shu; Yu Jiang; Shilin Deng; Tingnan Chen; Jingyao Liang; Xibao Zhang
delete分享
delete收藏
Hemophagocytic Lymphohistiocytosis Triggered by HSV‑1 in a Patient with Refractory Crohn’s Disease After Long‑Term Sequential Immunosuppressive Therapy由HSV-1触发的难治性克罗恩病患者长期序贯免疫抑制治疗后发生的噬血细胞性淋巴组织细胞增生症
deleteBiologics-Targets & Therapy
IF3.4
delete2026-07-30
delete0
deleteOAAI
deleteLingya Yao; Hanxiao Tu; Qian Cao
delete分享
delete收藏
Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program托扎卡单抗（一种抗IL-33单克隆抗体）的安全性分析：FRONTIER II期研究的数据
deleteBiologics-Targets & Therapy
IF3.4
delete2026-07-27
delete0
deleteOAAI
deleteRajesh Patel; Dennis Brooks; Elise Gorseth; Rachel Moate; Alexis Hofherr; Chris Kell; Gabriela Luporini Saraiva; Hitesh Pandya; Martin Jenkins; Ioannis Psallidas
delete分享
delete收藏
Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli; and Developing an Immunization Protocol for the Production of Optimal Humoral Response重组人干扰素-γ在E. coli中的表达与纯化优化；以及建立产生最佳体液免疫应答的免疫方案
deleteBiologics-Targets & Therapy
IF3.4
delete2026-04-16
delete0
deleteOAAI
deleteVanessa Uwituze; Claire M Mugasa; Monica Namayanja; David Paul Nalumenya; Jerome Ndayisenga; Kenneth Ssekatawa; Charles Drago Kato
delete分享
delete收藏
Bovine Milk Exosomes as Natural Cytoprotective Nanoplatforms Against Lead-Induced Toxicity牛乳外泌体作为对抗铅诱导毒性的天然细胞保护纳米平台
deleteBiologics-Targets & Therapy
IF3.4
delete2026-01-01
delete0
PREAI
deletePanda, Subhrajita; Ahmad, Faraz
delete分享
delete收藏
Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development美国食品药品监督管理局（FDA）第三阶段豁免对单克隆抗体生物类似药开发的净现值影响
deleteBiologics-Targets & Therapy
IF3.4
delete2026-01-01
delete0
PREAI
deleteRanbhor, Ranjit; Kulkarni, Priyanka
delete分享
delete收藏